Literature DB >> 19165430

[Current strategies in the treatment of atrial fibrillation].

Imke Drewitz1, Thomas Rostock, Boris Hoffmann, Daniel Steven, Helge Servatius, Thomas Meinertz, Stephan Willems.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19165430     DOI： 10.1007/s00063-008-1123-y

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN： 0723-5003


× No keyword cloud information.
  53 in total

1.  The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation.

Authors:  F I Marcus
Journal:  Am J Cardiol       Date:  1990-08-01       Impact factor: 2.778

Review 2.  Should atrial fibrillation ablation be considered first-line therapy for some patients? Why atrial fibrillation ablation should be considered first-line therapy for some patients.

Authors:  Atul Verma; Andrea Natale
Journal:  Circulation       Date:  2005-08-23       Impact factor: 29.690

3.  Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination.

Authors:  Michel Haïssaguerre; Prashanthan Sanders; Mélèze Hocini; Yoshihide Takahashi; Martin Rotter; Frederic Sacher; Thomas Rostock; Li-Fern Hsu; Pierre Bordachar; Sylvain Reuter; Raymond Roudaut; Jacques Clémenty; Pierre Jaïs
Journal:  J Cardiovasc Electrophysiol       Date:  2005-11

4.  Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias.

Authors:  Michel Haïssaguerre; Mélèze Hocini; Prashanthan Sanders; Frederic Sacher; Martin Rotter; Yoshihide Takahashi; Thomas Rostock; Li-Fern Hsu; Pierre Bordachar; Sylvain Reuter; Raymond Roudaut; Jacques Clémenty; Pierre Jaïs
Journal:  J Cardiovasc Electrophysiol       Date:  2005-11

5.  Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation.

Authors:  S Juul-Möller; N Edvardsson; N Rehnqvist-Ahlberg
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

6.  Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison.

Authors:  Stephan Willems; Hanno Klemm; Thomas Rostock; Benedikt Brandstrup; Rodolfo Ventura; Daniel Steven; Tim Risius; Boris Lutomsky; Thomas Meinertz
Journal:  Eur Heart J       Date:  2006-06-16       Impact factor: 29.983

7.  Electrophysiological breakthroughs from the left atrium to the pulmonary veins.

Authors:  M Haïssaguerre; D C Shah; P Jaïs; M Hocini; T Yamane; I Deisenhofer; M Chauvin; S Garrigue; J Clémenty
Journal:  Circulation       Date:  2000-11-14       Impact factor: 29.690

8.  Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation.

Authors:  Hakan Oral; Christoph Scharf; Aman Chugh; Burr Hall; Peter Cheung; Eric Good; Srikar Veerareddy; Frank Pelosi; Fred Morady
Journal:  Circulation       Date:  2003-10-13       Impact factor: 29.690

9.  Mechanisms of organized left atrial tachycardias occurring after pulmonary vein isolation.

Authors:  Edward P Gerstenfeld; David J Callans; Sanjay Dixit; Andrea M Russo; Hemal Nayak; David Lin; Ward Pulliam; Sultan Siddique; Francis E Marchlinski
Journal:  Circulation       Date:  2004-09-07       Impact factor: 29.690

10.  Usefulness of propafenone for recurrent paroxysmal atrial fibrillation.

Authors:  S J Connolly; D L Hoffert
Journal:  Am J Cardiol       Date:  1989-04-01       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.